Aimee Campbell
Overview
Explore the profile of Aimee Campbell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
196
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hefner K, Choo T, Shmueli-Blumberg D, Pavlicova M, King J, Fishman M, et al.
Drug Alcohol Depend Rep
. 2023 Jan;
5.
PMID: 36644220
Introduction: Psychosocial support is recommended in conjunction with medication for opioid use disorder (MOUD), although optimal "dose," modality, and timing of participation is not established. This study comprised a secondary...
2.
Mandavia A, Campbell A, Henry B, Chaple M, Hunt T, Arout C, et al.
J Behav Health Serv Res
. 2022 Feb;
49(3):414-415.
PMID: 35199281
No abstract available.
3.
Mandavia A, Campbell A, Henry B, Chaple M, Hunt T, Arout C, et al.
J Behav Health Serv Res
. 2022 Feb;
49(3):262-281.
PMID: 35112221
This study aims to describe which substance use service (SUS) organizations and who within these organizations support the maintenance of policies targeted at improving substance use treatment services. An online...
4.
Luderer H, Chiodo L, Wilson A, Brezing C, Martinez S, Xiong X, et al.
JMIR Res Protoc
. 2022 Jan;
11(1):e32759.
PMID: 35080499
Background: Prescription digital therapeutics are software-based disease treatments that are regulated by the US Food and Drug Administration; the reSET-O prescription digital therapeutic was authorized in 2018 and delivers behavioral...
5.
Roache J, Pavlicova M, Campbell A, Choo T, Peavy M, Kermack A, et al.
Alcohol Clin Exp Res
. 2021 Oct;
45(12):2569-2578.
PMID: 34698397
Background: The comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT) trial showed that following induction, treatment with the sublingual agonist (buprenorphine-naloxone, BUP-NX) or injected antagonist (extended...
6.
Karway G, Ivanova J, Bhowmik A, Murcko A, Saks M, McCarty D, et al.
J Addict Med
. 2021 Jul;
16(3):261-271.
PMID: 34261889
Objectives: Title 42 Code of Federal Regulations Part 2 (42 CFR Part 2 or Part 2) was enacted in 1975 to protect patients receiving treatment for substance use disorders. A...
7.
Henry B, Campbell A, Hunt T, Johnson J, Mandavia A, Chaple M, et al.
J Subst Abuse Treat
. 2021 Jul;
133:108550.
PMID: 34215475
Introduction: Due to the COVID-19 pandemic, regulations for substance use services changed to accommodate stay-at-home orders and physical distancing guidelines. Methods: Using in-depth interviews (N = 14) and framework analysis,...
8.
Marino L, Gukasyan N, Hu M, Campbell A, Pavlicova M, Nunes E
Subst Use Misuse
. 2021 Apr;
56(9):1258-1265.
PMID: 33882788
Background: Mental health issues in individuals with substance use disorders are common and can affect treatment outcomes. Objectives: Secondary analysis of a multi-center trial of an internet-delivered psychosocial SUD treatment...
9.
Scharfstein D, Steingrimsson J, McDermott A, Wang C, Ray S, Campbell A, et al.
Biometrics
. 2021 Mar;
78(2):649-659.
PMID: 33728637
In this paper, we present a method for conducting global sensitivity analysis of randomized trials in which binary outcomes are scheduled to be collected on participants at prespecified points in...
10.
Rudolph K, Diaz I, Hejazi N, van der Laan M, Luo S, Shulman M, et al.
Addiction
. 2020 Dec;
116(8):2094-2103.
PMID: 33340181
Background And Aims: A recent study found that homeless individuals with opioid use disorder (OUD) had a lower risk of relapse on extended-release naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX), whereas non-homeless...